Avanos Medical (NYSE: AVNS) had raised his price target by Morgan Stanley from $ 58.00 to $ 60.00 in a report released on Wednesday, August 8th. The company currently has an underweight in the shares.
Apart from that, KeyCorp increased their price target at Avanos Medical from $ 66.00 to $ 75.00 and gave the company an overweight rating in a report on Wednesday, August 8th.
NYSE AVNS opened Wednesday at $ 72.29. The company has a market capitalization of $ 3.38 billion, a P / E ratio of 30.76 and a beta of 1.60. Avanos Medical has a 12-month low of $ 41.51 and a 12-month high of $ 72.75. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.48 and a quick ratio of 2.18.
An institutional investor recently bought a new position in the shares of Avanos Medical. Government officials Retirement System of Ohio acquired a new stake in Avanos Medical Inc. (NYSE: AVNS) in the second quarter, according to the most recent 13F application to the Securities and Exchange Commission (SEC). The institutional investor acquired 2,372 shares of the company's shares, valued at approximately $ 136,000. 89.91% of the shares are held by institutional investors and hedge funds.
Avanos Medical Company profile
Avanos Medical, Inc. operates as a medical technology company focused on eliminating pain, accelerating recovery and preventing infection for healthcare professionals and patients worldwide. The Medical Devices segment offers a portfolio of products that focus on the health of the airways and digestion, alongside surgical and interventional pain management.
Recommended story: Asset allocation
Receive news and ratings for Avanos Medical Daily – Enter your email address below to receive a concise, daily summary of the latest news and analyst reviews for Avanos Medical and related companies with the FREE daily email newsletter from MarketBeat.com.